INNV-18. PROLONGED REMISSION AFTER TREATMENT WITH SINGLE-AGENT IBRUTINIB AS MAINTENANCE THERAPY FOLLOWING SALVAGE RADIATION THERAPY FOR REFRACTORY/RELAPSE PRIMARY CNS LYMPHOMA
نویسندگان
چکیده
Abstract INTRODUCTION Primary central nervous system lymphoma (PCNSL) is a rare and aggressive disease. Standard induction therapy for PCNSL consists of high-dose methotrexate-based (HD-MTX) regimen. For relapsed or refractory primary CNS (r/r PCNSL), most the non-standard treatment regimens including additional chemotherapy, stem cell transplant, whole brain radiation (WBRT) may not reach long-term remission due to intolerance by patients lack effects. Here we report case with r/r reached more than 50-month after salvage WBRT followed single agent ibrutinib maintenance therapy. CASE REPORT: 75-year-old female PCNSL, experienced disease recurrence, despite undergoing multiple lines initial HD-MTX, second-line rituximab temozolomide, repeated clinical trial. Because her was these options, decided start as therapy, which resulted in significant reduction tumor burden. Prior studies, however, showed that who underwent alone had median survival only 1-2 years. Therefore, extend WBRT, she opted try ibrutinib, Bruton’s tyrosine kinase inhibitor past success treating patients, WBRT. She tolerated well be off 18 month-maintenance The patient has been stable clinically. since survived 50 months completion plus ibrutinib. DISCUSSION Compared prior reports 11 16 our prolonged survival, supports potential positive effect
منابع مشابه
Primary dural lymphoma: Complete remission after treatment with radiation therapy.
Central nervous system (CNS) involvement in sarcoidosis is rare and typically occurs in 5-10% of patients. Neurological symptoms in a patient with known sarcoidosis can be attributed to neurosarcoidosis without thorough evaluation. Primary Dural Lymphoma (PDL) is an extremely rare form of non-Hodgkin lymphoma. Although PDL is technically a subtype of primary CNS lymphoma, the two entities vary ...
متن کاملProspective trial on topotecan salvage therapy in primary CNS lymphoma.
BACKGROUND Standard salvage therapy has not been established for recurrent primary central nervous system lymphoma (PCNSL). We report the final results of a prospective study on topotecan chemotherapy in relapsed or refractory PCNSL. PATIENTS AND METHODS The study included 27 patients with a median age of 51 years and an ECOG performance status of 2. Fourteen patients were refractory to the l...
متن کاملTreatment failure after primary and salvage therapy for prostate cancer.
BACKGROUND The authors report the likelihood of treatment failure and the outcomes after salvage therapy among men with prostate cancer who initially either received external-beam radiation therapy (EBRT) or underwent radical prostatectomy (RP). METHODS Using a national disease registry, the Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) database, 5277 men with prosta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-oncology
سال: 2022
ISSN: ['1523-5866', '1522-8517']
DOI: https://doi.org/10.1093/neuonc/noac209.558